Skip to content
10-Q

Quarterly Report

TherapeuticsMD, Inc. TXMD

0001213900-25-109381

← back to feed
Filed
Nov 12, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2025 · Nov 11, 2025 11.57M sh
Shares Diluted Q3 2025 · Sep 30, 2025 11.57M sh
Shares Diluted Q3 2025 · Sep 30, 2025 11.57M sh
Shares Diluted Q3 2025 · Sep 30, 2024 11.53M sh
Shares Diluted Q3 2025 · Sep 30, 2024 11.53M sh
Stockholders Equity Q3 2025 · Sep 30, 2025 $27.44M
Stockholders Equity Q3 2025 · Jun 30, 2025 $27.29M
Stockholders Equity Q3 2025 · Mar 31, 2025 $26.74M
Stockholders Equity Q3 2025 · Dec 31, 2024 $27.37M
Stockholders Equity Q3 2025 · Sep 30, 2024 $27.09M
Stockholders Equity Q3 2025 · Jun 30, 2024 $27.67M
Stockholders Equity Q3 2025 · Mar 31, 2024 $28.66M
Stockholders Equity Q3 2025 · Dec 31, 2023 $29.29M
Current Liabilities Q3 2025 · Sep 30, 2025 $4.95M
Current Liabilities Q3 2025 · Dec 31, 2024 $5.17M
Total Liabilities Q3 2025 · Sep 30, 2025 $11.23M
Total Liabilities Q3 2025 · Dec 31, 2024 $11.45M
Current Assets Q3 2025 · Sep 30, 2025 $14.5M
Current Assets Q3 2025 · Dec 31, 2024 $12.26M
Total Assets Q3 2025 · Sep 30, 2025 $38.67M
Total Assets Q3 2025 · Dec 31, 2024 $38.82M
Eps Diluted Q3 2025 · Sep 30, 2025 $0.01
Eps Diluted Q3 2025 · Sep 30, 2025 $0.00
Eps Diluted Q3 2025 · Sep 30, 2024 −$0.05
Eps Diluted Q3 2025 · Sep 30, 2024 −$0.21
Eps Basic Q3 2025 · Sep 30, 2025 $0.01
Eps Basic Q3 2025 · Sep 30, 2025 $0.00
Eps Basic Q3 2025 · Sep 30, 2024 −$0.05
Eps Basic Q3 2025 · Sep 30, 2024 −$0.21
Net Income Q3 2025 · Sep 30, 2025 $152K
Net Income Q3 2025 · Sep 30, 2025 $50K
Net Income Q3 2025 · Jun 30, 2025 $551K
Net Income Q3 2025 · Mar 31, 2025 −$653K
Net Income Q3 2025 · Sep 30, 2024 −$609K
Net Income Q3 2025 · Sep 30, 2024 −$2.43M
Net Income Q3 2025 · Jun 30, 2024 −$1.09M
Net Income Q3 2025 · Mar 31, 2024 −$734K
Operating Income Q3 2025 · Sep 30, 2025 −$862K
Operating Income Q3 2025 · Sep 30, 2025 −$2.84M
Operating Income Q3 2025 · Sep 30, 2024 −$1.13M
Operating Income Q3 2025 · Sep 30, 2024 −$5.46M